Cilostazol
Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood–brain barrier
[Cilostazol].
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients
Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease
Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood–brain barrier under hypoxia/reoxygenation
Cilostazol Promotes Vascular Smooth Muscles Cell Differentiation Through the cAMP Response Element-Binding Protein-Dependent Pathway
Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation
